Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mydayis in Bipolar Depression
NCT04235686Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHP465 mixed amphetamine salts in bipolar disorder (BD), sponsored by Mayo Clinic. Started Jul 2020; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04235686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235686.